Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397177 | 0.85 | KDM4C (0.41) | HSD17B10MAPTALDH1A1MAPK1POLB | |
| SCHEMBL3263632 | 0.79 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL24757293 | 0.75 | KDM4E (0.49) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL30964220 | 0.73 | MAPT (0.49) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL27140315 | 0.73 | PDE4D (0.59) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL10860621 | 0.72 | KDM4E (0.51) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL24906442 | 0.72 | PDE4D (0.53) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT | |
| SCHEMBL16270147 | 0.70 | KMT2A (0.49) | HSD17B10MAPTPDE4DHPGDHTT | |
| SCHEMBL5561961 | 0.70 | KMT2A (0.48) | CYP1A2MAPTPDE4DSMN1; SMN2ALDH1A1 | |
| SCHEMBL28802616 | 0.70 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3704112-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111630051-A | Spirocyclic compounds of alkenes as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | CYP1A2 488/4885CYP2C9 773/4885CYP2C19 973/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | CYP1A2 488/4885CYP2C9 773/4885CYP2C19 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.